Human Pheromone Sciences Q2
This article was originally published in The Rose Sheet
Executive Summary
Fragrances Realm and Inner Realm entering South Korean market as part of a long-term initiative to expand distribution into Asia, firm says. Disappointing sales in the U.S. and Far East coupled with delayed order shipments resulted in net loss of $118,000 in the second quarter compared to net income of $12,000 the prior year period, San Jose, Calif. company reports. Net sales declined 51.9% to $269,000. Despite negative short-term results, "we firmly believe in the viability and long-term value of our fragrance and toiletry products," company maintains...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.